VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.82 (−90.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Virax Biolabs Group Ltd grew revenue 96.2% to $12.42K over fiscal 2026. Free cash flow was -$4.88M.
Revenue
$12.42K
+96.2% vs. a year earlier
Operating income
-$6.40M
FY2026
Free cash flow
-$4.88M
FY2026
EPS, diluted
-$12.64
FY2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $12.42K
- Net income
- -$5.02M
- EPS, diluted
- -$12.64
- Free cash flow
- -$4.88M
Seven years at a glance
Fiscal years 2020 to 2026, USD
Revenue
$12.42K+96.2% YoY
Gross profit
$7.69K
Operating income
-$6.40M
Net income
-$5.02M
EPS, diluted
-$12.64
Free cash flow
-$4.88M
Reported period